Closing Strong: Mimedx Group Inc (MDXG) Ends at $6.97 on Tuesday

Kevin Freeman

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.83 million shares were traded. MDXG stock price reached its highest trading level at $7.07 during the session, while it also had its lowest trading level at $6.91.

Ratios:

Our goal is to gain a better understanding of MDXG by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.71. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 02, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.

On March 07, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12. On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.Craig Hallum initiated its Buy rating on October 27, 2023, with a $12 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’25 when Capper Joseph H bought 200,000 shares for $6.34 per share. The transaction valued at 1,268,000 led to the insider holds 529,530 shares of the business.

Maersk-Moller Kimberly sold 1,759 shares of MDXG for $14,142 on Mar 17 ’25. The Chief Commercial Officer now owns 309,077 shares after completing the transaction at $8.04 per share. On Mar 13 ’25, another insider, Hulse William Frank IV, who serves as the General Counsel and CAO of the company, sold 54,596 shares for $7.89 each. As a result, the insider received 430,762 and left with 440,178 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 1031274240 and an Enterprise Value of 930869120. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.31, and their Forward P/E ratio for the next fiscal year is 21.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.83 while its Price-to-Book (P/B) ratio in mrq is 4.76. Its current Enterprise Value per Revenue stands at 2.559 whereas that against EBITDA is 17.32.

Stock Price History:

The Beta on a monthly basis for MDXG is 1.74, which has changed by 0.1278317 over the last 52 weeks, in comparison to a change of 0.17594421 over the same period for the S&P500. Over the past 52 weeks, MDXG has reached a high of $10.14, while it has fallen to a 52-week low of $5.47. The 50-Day Moving Average of the stock is -0.22%, while the 200-Day Moving Average is calculated to be -7.91%.

Shares Statistics:

The stock has traded on average 734.92K shares per day over the past 3-months and 461190 shares per day over the last 10 days, according to various share statistics. A total of 147.92M shares are outstanding, with a floating share count of 116.46M. Insiders hold about 21.29% of the company’s shares, while institutions hold 51.53% stake in the company. Shares short for MDXG as of 1756425600 were 4975900 with a Short Ratio of 6.77, compared to 1753920000 on 4999921. Therefore, it implies a Short% of Shares Outstanding of 4975900 and a Short% of Float of 4.21.

Earnings Estimates

The current rating of Mimedx Group Inc (MDXG) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.09, with high estimates of $0.09 and low estimates of $0.08.

Analysts are recommending an EPS of between $0.33 and $0.32 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.35, with 2.0 analysts recommending between $0.36 and $0.34.

Revenue Estimates

5 analysts predict $94.73M in revenue for the current quarter. It ranges from a high estimate of $97.2M to a low estimate of $93.4M. As of the current estimate, Mimedx Group Inc’s year-ago sales were $84.06MFor the next quarter, 5 analysts are estimating revenue of $104.97M. There is a high estimate of $107M for the next quarter, whereas the lowest estimate is $102.75M.

A total of 5 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $391M, while the lowest revenue estimate was $384.33M, resulting in an average revenue estimate of $386.53M. In the same quarter a year ago, actual revenue was $348.88MBased on 5 analysts’ estimates, the company’s revenue will be $418.56M in the next fiscal year. The high estimate is $432M and the low estimate is $407.1M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.